STOCK TITAN

TCC releases 2023 Economic Outlook: Serious risks for U.S. economy as recession looms

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Negative)
Tags

What leaders can do to not destroy corporate value

MENLO PARK, Calif.--(BUSINESS WIRE)--

Supply chain funding company Trade Capital Corporation (TCC) today released its 2023 Economic Outlook, warning of a serious risks to the economy as the U.S. appears headed for a recession in 2023, facing, among other risks, inflation and demand compression. The report also details how corporate leaders can mitigate risks and increase resiliency.

TCC makes 20 predictions for the year ahead, including muted growth for U.S. GDP, new opportunities in global trade with Emerging Markets thanks to a restructuring in supply chains, and continued disruptions of crucial supply chains amid instability as the Russo-Ukraine war drags into a second year. Corporate executives now must contend with pressures on energy prices, higher interest rates, and inflation.

Read the full TCC 2023 Economic Outlook

“At TCC we believe ‘cash is king’. Companies need to get back to basics in these uncertain times, hedge against risks and rising prices. We see our clients want to advance purchases and their suppliers want to get paid faster. Executives would do well to embrace capital-efficient business models and preserve liquidity now, and TCC is uniquely positioned to provide both funding and supply chain efficiencies,” said Sanjay Bonde, TCC’s co-founder and CEO.

Mr. Bonde will host a discussion on how leaders can take strategies to succeed in the new economic reality at TCC’s upcoming online event:

TCC Leadership Series
“How to not destroy corporate value in 2023”
Thursday, February 2, 2023 at 8 AM PST / 11 AM EST
with distinguished panelists
Dr. Yossi Feinberg, Professor of Economics, The Adadams Distinguished Professor of Management at Stanford Graduate School of Business

Aris Kekedjian, former CEO of Icahn Enterprises; former CIO at GE; Chairman and CEO of Trinity Biotech

Space is limited. Reserve your seat now.

About TCC

TCC and its wholly-owned trading arm TradeCo deliver Capital as a Service (CaaS) in an integrated supply chain technology platform. TCC’s CaaS™ solution offers access to cash flow, providing manufacturers with liquidity and capital efficiency – while its end-to-end technology platform enables procurement, logistics, warehousing, track and trace, planning and forecasting as well as integration with third-party logistics providers to deliver comprehensive, end-to-end supply chain services. TCC’s CaaS Wallet™ business suite of solutions includes the Inventory Card™, Factoring Card™ and SupplierPay Card™ to monetize and secure inventory, accelerate supplier payments and create more resilient supply chain ecosystems.

For more information visit us:

www.tradecapitalcorp.com | LinkedIn | Facebook | Twitter | Instagram

Giang Nguyen

VP Marketing and Communications

Email: press@tradecapitalcorp.com

Phone: +1(650) 549-1247

Source: Trade Capital Corporation

Trinity Biotech Plc

NASDAQ:TRIB

TRIB Rankings

TRIB Latest News

TRIB Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Ireland
Bray

About TRIB

since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the